USP 788 ÀÔÀÚ ¸ð´ÏÅ͸µ ¿ä°Ç
ºñ°æ±¸½Ä ¼Ö·ç¼Ç ¿ÏÁ¦Ç°À» Å×½ºÆ®Çϱâ À§Çؼ´Â USP 788°ú, À¯·´ ±ÔÁ¤À» ÃæÁ·½ÃÄÑ¾ß ÇÒ °æ¿ì¿¡´Â EP 5.1À» ÁؼöÇØ¾ß ÇÕ´Ï´Ù. ¾Æ·¡ ¹®¼, ºñ°æ±¸½Ä ¼Ö·ç¼ÇÀÇ ÀÔÀÚ °è¼ö´Â Ç¥ÁØ°ú °ü·ÃµÈ ¹®Á¦Á¡°ú ¿ä°ÇÀ» ¼³¸íÇÏ°í, ±¤Â÷´Ü ÀÔÀÚ °è¼ö±â¸¦ ÀÌ¿ëÇÏ¿© ÀÌ·¯ÇÑ Ç¥ÁØÀ» ÁؼöÇÏ´Â ¹æ¹ý¿¡ ´ëÇØ ³íÀÇÇÏ°í ÀÖ½À´Ï´Ù.
USP 788¿¡ ´ëÇØ ´õ ¸¹Àº Á¤º¸°¡ ÇÊ¿äÇϰųª Á¦¾à¿ë ¸ð´ÏÅ͸µ¿¡ °üÇÏ¿© Ưº°ÇÑ ¹®ÀÇ »çÇ×ÀÌ ÀÖÀ¸¸é, Á¦¾à °ü·Ã Àü¹®°¡ÀÎ Mark Hallworth ¾¾¿¡°Ô ¿¬¶ôÇϽʽÿÀ. ÀüÈ: 303.443.7100 ¶Ç´Â ÀüÀÚ¸ÞÀÏ: mhallworth@pmeasuring.com.
¹®¼
|
ºñ°æ±¸½Ä ¼Ö·ç¼Ç¿¡¼ÀÇ ÀÔÀÚ °è¼ö (244.3 KB) Learn about the requirements laid out by US (USP), European (EP), and Japanese (JP) Pharmacopoeia standards, including the most recent USP 788 (April 2007), EP 5.1 and JP 15 release information. These standards demand that injectable solutions are effectively monitored for microcontamination, specifically ... ¸ðµç Ç¥¿Í ±×¸²ÀÌ ÀÖ´Â À§ ÆÄÀÏÀ» ´Ù¿î·ÎµåÇϽʽÿÀ. ¾Æ·¡ HTML ¹öÀüÀº °£´ÜÇÑ °³¿ä ¹öÀüÀÔ´Ï´Ù: HTML ¹öÀü . |
|
ÀÔÀÚ °è¼ö¿¡ ´ëÇÑ ±âº» ¾È³»¼ (2.4 MB) ¸ðµç Ç¥¿Í ±×¸²ÀÌ ÀÖ´Â À§ ÆÄÀÏÀ» ´Ù¿î·ÎµåÇϽʽÿÀ. ¾Æ·¡ HTML ¹öÀüÀº °£´ÜÇÑ °³¿ä ¹öÀüÀÔ´Ï´Ù: HTML ¹öÀü . |
Á¦Ç°
SamplerSight ÀÔÀÚ ¸ð´ÏÅ͸µ ¼ÒÇÁÆ®¿þ¾îÈ÷½ºÅä±×·¥, ŸÀÔ ÇÃ·Ô ¹× Ç¥ µ¥ÀÌÅÍ°¡ ¼ö·ÏµÈ ¹èÄ¡ ±â¹ÝÀÇ ¾×ü ÀÔü °è¼ö ½Ã½ºÅÛ Á¤º¸¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ °³°ü Á¦°ø |
||
Á¦¾à¿ë ÀÔÀÚ °è¼ö¸¦ À§ÇÑ ºñ°æ±¸½Ä ÀÚµ¿ »ùÇøµ ½Ã½ºÅÛ ( APSS-200 )SamplerSight-Pharma°ú ÇÔ²²ÇÏ´Â APSS-200 ½Ã¸°Áö »ùÇøµ. ½Ã½ºÅÛÀº ±¤¹üÀ§ÇÑ ¾×ü¿¡¼ ºÎÀ¯ ¹Ì¸³ÀÚ¸¦ »çÀÌ¡ÇÏ°í °è¼öÇϱâ À§ÇØ ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ ½Ã½ºÅÛ ÇöÀçÀÇ USP½ÃÇè XXV <788> ¿ä±¸»çÇ×À» ÁؼöÇϰųª ÃÊ°úÇÏ¸ç ¹Ì·¡ÀÇ ±ÔÁ¦ º¯°æ¿¡ ½±°Ô ÀûÀÀÇϵµ·Ï ¸¸µé¾îÁ³½À´Ï´Ù. APSS-200 ½Ã½ºÅÛÀº LS-200 ½Ã¸°Áö »ùÇ÷¯, LiQuilaz ¿ëÀûÃøÁ¤ »ùÇ÷¯, ±×¸®°í APSS-SamplerSight-Pharma ¼ÒÇÁÆ®¿þ¾î·Î ÀÌ·ç¾îÁ³À¸¸ç ÇöÀçÀÇ FDA 21CFR Part 11 "ÀüÀÚ ±â·Ï ¹× ¼¸í" ±ÔÁ¦¸¦ ÁؼöÇÕ´Ï´Ù. |
¼ºñ½º
ÀÌ À¥»çÀÌÆ®ÀÇ Á¤º¸´Â ¿¹°í¾øÀÌ º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.
